Can BMY's First CELMoD Approval Support Its Growth Strategy?
Bristol Myers Squibb received FDA accelerated approval for Zenbexus, the first CELMoD therapy, after data showed it doubles MRD-negative complete response rates.
Why it matters — This approval marks a milestone for BMY's CELMoD platform, potentially supporting the company's broader growth strategy with a novel therapy class.